相关实验视频

Updated: May 31, 2025

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

在晚期食道状细胞癌中探索新型免疫疗法:针对TIGIT是否是一个答案?

Chien-Huai Chuang^1,2,3, Jhe-Cyuan Guo^1,2, Ken Kato^4,5

¹Department of Medical Oncology, National Taiwan University Cancer Center, 7 Chung-Shan South Road, Taipei, 10002, Taiwan.

Esophagus : official journal of the Japan Esophageal Society

|January 23, 2025

概括

新的免疫检查点抑制剂,包括TIGIT,对晚期食道状细胞癌 (ESCC) 有希望. 将抗TIGIT与抗PD-1疗法结合在一起具有潜力,但需要进一步的研究来确认其在一线治疗中的作用.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
胃肠道癌症胃肠道癌症

背景情况:

食道状细胞癌 (ESCC) 是癌症死亡的主要原因,特别是在亚洲.
免疫检查点抑制剂 (ICI),如抗PD-1和抗CTLA-4,已经彻底改变了ESCC治疗.
针对TIGIT/PVR等途径的新型ICI正在成为有前途的治疗策略.

研究的目的:

评估新型免疫检查点抑制剂的疗效和安全性,特别是抗TIGIT,与先进ESCC的现有疗法相结合.
探索双重封锁策略 (如TIGIT和PD-1) 在增强抗瘤反应方面的潜力.
确定抗TIGIT治疗在先进和地方区域ESCC环境中的最佳作用.

主要方法:

对TIGIT/PVR通路封锁的临床前数据的审查.
对研究抗TIGIT与抗PD-1/PD-L1和化疗的组合的临床试验结果的分析.
审查正在进行的研究在先进和地方区域的ESCC.

主要成果:

在临床前模型中,TIGIT和PD-1的双重阻断显示了增强的抗瘤免疫反应.
抗TIGIT与抗PD-1/PD-L1的组合已在晚期ESCC患者中显示出临床反应.
双重ICI加上化疗的第一线组合在II/III期试验中显示出有前途的活性和可接受的毒性.

结论:

抗TIGIT与抗PD-1/PD-L1加上化疗相结合,代表了先进的ESCC第一线治疗的潜在进步.
需要进行进一步的临床试验,以确定将抗TIGIT添加到当前护理标准中的最终作用.
优化抗TIGIT治疗需要识别预测生物标志物,确定最佳抗体组合,并了解ESCC和其他癌症的机制性见解.

关键词:

食道状细胞癌;免疫检查点抑制剂.免疫治疗是一种免疫疗法.具有Ig和ITIM域的T细胞免疫受体.

更多相关视频

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor

Published on: May 2, 2022

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...